Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
Rhea-AI Summary
Trinity Biotech (Nasdaq: TRIB) announced on June 29, 2026 that it has given formal notice to terminate its Standby Equity Purchase Agreement (SEPA) with YA II PN, an affiliate of Yorkville Advisors Global, ending its related equity line of credit facility.
The company does not intend to use the SEPA further, and indicates that the termination aligns with its current financing strategy.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- Termination of SEPA removes access to the related equity line of credit facility
News Market Reaction – TRIB
On the day this news was published, TRIB gained 15.73%, reflecting a significant positive market reaction. Argus tracked a peak move of +36.4% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $9.11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Peers on Argus
TRIB was up before this filing, while close peers showed mixed moves (several down, some sharply up), indicating the stock’s behavior was more company‑specific than part of a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | AI business launch | Positive | -39.0% | Launch of Trinovium subsidiary targeting AI data center liquid cooling market. |
| Jun 16 | Earnings and orders | Positive | -15.8% | Q1 revenue growth, margin improvement, and large TrinScreen HIV test orders. |
| May 01 | Leadership change | Neutral | +1.3% | Appointment of new head of North America commercial operations. |
| Mar 23 | Clinical results | Positive | -5.1% | Successful enhanced EpiCapture prostate cancer test clinical results. |
| Mar 18 | Collaboration deal | Positive | -7.0% | Collaboration to commercialize biomarkers for earlier Sjögren’s Syndrome detection. |
Recent positive operational and strategic updates have often been followed by negative share price reactions, suggesting a pattern of divergence from headline sentiment.
Regulatory & Risk Context
Reported short interest is categorized as low, implying limited short-squeeze potential and suggesting that short covering alone is unlikely to drive significant volatility.
An effective Form F-3 shelf and Standby Equity Purchase Agreement allow the company, at its option, to sell ADSs for up to $25,000,000 in gross proceeds, while registered resales by YA II PN, Ltd. provide no proceeds to the company.
Market Pulse Summary
The stock surged +15.7% in the session following this news. A strong positive reaction aligns with relief over ending the Yorkville Standby Equity Purchase Agreement, given prior registration of 33,752,429 ADSs linked to it and alternative financing via a $4,352,314 ATM and effective $25,000,000 shelf.
Key Terms
standby equity purchase agreement financial
equity line of credit facility financial
AI-generated analysis. Not financial advice.
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.
The Company has determined that it does not intend to make any further use of the SEPA. Accordingly, termination of the equity line of credit facility reflects the Company’s current financing strategy.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to successfully develop and commercialize data center cooling & thermal management solutions for AI and high-performance computing, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the Company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties, and risks related to the condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2025 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc. Through its Trinovium subsidiary, Trinity Biotech is extending its fluid manufacturing and analytical capabilities into advanced liquid cooling solutions for AI data center infrastructure. Trinity Biotech sells directly in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please visit www.trinitybiotech.com.
.
| Contact: | Trinity Biotech plc | RedChip Companies Inc. |
| Paul Murphy | Dave Gentry, CEO | |
| (353)-1-2769800 | (1)-407-644-4256 | |
| (1)-800-RED-CHIP (733-2447) | ||
| TRIB@redchip.com |
